| noncationic LPs |
DOPC |
Al(III) phthalocyanine
chloride disulfonic acid (AlPcS2a) |
siRNA |
HepG2 SK-HEP-1 cell lines |
minimizing off-target effects
and providing selectivity to
hepatoma cancer cells |
(73) |
| CRISPER/Cas 9 liposomes |
DOTAP, DOPE,
cholesterol |
verteporfin (VP) |
CRISPER/CAS
9 sgRNA against TNFAIP3 |
HEK293 cell lines |
increased knockdown efficiency |
(74) |
| TAT peptide-modified Lipid Encapsulated
Gold Nanoparticles |
AuNPs (DOTAP, DOPE, cholesterol,
PEG2000-DSPE |
gold |
CRISPER/CAS 9sgRNA-targeting
Plk-1 |
Melanoma cell lines and in vivo tumor model |
Plk-1 knockout and tumor suppression in vitro and in vivo
|
(75) |
| light-triggerable liposome
(lipVP) |
DOPC DOTAP |
verteporfin (VP) |
antisense oligonucleotides against PAC1R |
PC12
cell lines |
increased PAC1R repression efficiency |
(76) |
| X-ray
triggerable liposomes |
DOPC DOTAP |
verteporfin
(VP) |
antisense oligonucleotides Against PAC1R |
PC12 HCT 116 cell lines |
increased PAC1R repression
efficiency |
(77) |
| liposome–polycation–DNA (LPD) nanocomplexes |
DOTAP, PEGylated neutral lipid and cholesterol |
Verteporfin (VP) |
polyethylenimine (PEI)/plasmid DNA
(pDNA) encoding EGFP |
HCT116 cell lines |
improves transfection efficiency |
(46) |
